Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00000975
Other study ID # ACTG 120
Secondary ID 11095
Status Completed
Phase Phase 2
First received
Last updated
Est. completion date September 1994

Study information

Verified date October 2021
Source National Institute of Allergy and Infectious Diseases (NIAID)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the feasibility of itraconazole as (1) primary therapy in histoplasmosis and (2) maintenance therapy after completion of primary therapy. To evaluate the effect of therapy of CNS histoplasmosis. To determine if resistance to drug occurs in patients who fail therapy. Histoplasmosis is a serious opportunistic infection in patients with AIDS. Although the clinical response to amphotericin B treatment in the AIDS patients is generally good, administration difficulties and toxicity detract from its usefulness. Oral treatment with ketoconazole overcomes these limitations of amphotericin B, but does not appear to be effective for primary treatment in patients with AIDS. Itraconazole is a triazole compound in which preclinical studies have demonstrated activity against Histoplasmosis capsulatum. Preclinical studies have also shown that itraconazole appears effective in the treatment of histoplasmosis. The frequency of adverse reactions to itraconazole has been low in several studies. Central nervous system (CNS) involvement occurs in up to 20 percent of patients with histoplasmosis, and appears to have a poor response to amphotericin B treatment. Itraconazole has been used successfully in a small number of patients with cryptococcal meningitis, supporting a study of its use in CNS histoplasmosis.


Description:

Histoplasmosis is a serious opportunistic infection in patients with AIDS. Although the clinical response to amphotericin B treatment in the AIDS patients is generally good, administration difficulties and toxicity detract from its usefulness. Oral treatment with ketoconazole overcomes these limitations of amphotericin B, but does not appear to be effective for primary treatment in patients with AIDS. Itraconazole is a triazole compound in which preclinical studies have demonstrated activity against Histoplasmosis capsulatum. Preclinical studies have also shown that itraconazole appears effective in the treatment of histoplasmosis. The frequency of adverse reactions to itraconazole has been low in several studies. Central nervous system (CNS) involvement occurs in up to 20 percent of patients with histoplasmosis, and appears to have a poor response to amphotericin B treatment. Itraconazole has been used successfully in a small number of patients with cryptococcal meningitis, supporting a study of its use in CNS histoplasmosis. At least 30 patients with AIDS and an initial episode of disseminated histoplasmosis are selected for this study. Up to 5 patients will have a diagnosis of CNS histoplasmosis. Therapy with all other systemic antifungal agents must be halted before study entry. Patients receive itraconazole for 3 days followed by daily oral doses for a total of 12 weeks. Patients who are doing well clinically, without evidence of clinical failure or dose-limiting toxicity, are permitted to continue maintenance therapy to prevent relapse at a reduced dose for an additional 12 months. Patients who are being treated for CNS histoplasmosis will continue to receive itraconazole.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date September 1994
Est. primary completion date
Accepts healthy volunteers No
Gender All
Age group 13 Years and older
Eligibility Inclusion Criteria Concurrent Medication: Allowed: - Vincristine, vinblastine, bleomycin, or interferon for Kaposi's sarcoma. - Erythropoietin. - Didanosine by exemption for 10 patients. - Barbiturates. - Coumarin-type anticoagulants. - Oral contraceptives. - Digoxin. - Methadone. - Narcotics. - Acyclovir. - Acetaminophen. - Sulfonamides. - Trimethoprim / sulfamethoxazole. - Pentamidine for Pneumocystis carinii pneumonia (PCP) or PCP prophylaxis. - Topical antifungals. - Pyrimethamine. - Ganciclovir. - AZT. - Stress doses of steroids in patients with adrenal insufficiency. Concurrent Treatment: Allowed: - Dose reduction or interruption of myelosuppressive therapy and transfusion to maintain hemoglobin of 7 or more g/dl. - Radiation therapy. Patient must: - Show laboratory evidence of HIV infection and disseminated histoplasmosis. - Be oriented to person, place, and time. - Be able to give written informed consent (appropriate consent must be obtained from a parent or legal guardian for patients under 18 years of age). Allowed: - Abnormal liver function tests in Grade 3 toxicity range if liver biopsy shows evidence that histoplasmosis caused these abnormalities. - Mucocutaneous candidiasis. Prior Medication: Allowed: - Amphotericin B or ketoconazole for pulmonary histoplasmosis at least 3 months prior to study entry. - Azidothymidine (AZT). - Vincristine, vinblastine, bleomycin, or interferon for mucocutaneous Kaposi's sarcoma. - Prophylaxis for Pneumocystis carinii pneumonia (PCP). Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: - Severely ill, or at risk of dying from histoplasmosis within the first week of treatment, as indicated by systolic blood pressure less than 90 mm Hg , or PO2 less than 60. - Active CNS lesions, malignancies, or infections other than MAI. - Severe malabsorption syndrome (persistent diarrhea more than 4 weeks duration with at least 4 loose stools per day accompanied by a 10 percent or greater weight loss). - Requiring cytotoxic therapy for malignancies. - Any systemic fungal infection other than histoplasmosis. - Systemic Mycobacterium avium intracellulare. - Receiving treatment for other acute opportunistic infections whose signs and symptoms have not yet resolved or stabilized. - History of allergy to or intolerance of imidazoles or azoles. Concurrent Medication: Excluded: - All other systemic antifungal agents. - Investigational drugs not specifically allowed. - Oral hypoglycemics. - Rifamycins. - Phenytoin. - Carbamazepine. - Steroids in excess of physiologic replacement doses not specifically allowed. - Cytotoxic chemotherapy. - Discouraged: - Antacids. - Sucralfate. - H2 blockers. Patients with the following are excluded: - Severely ill, or at risk of dying from histoplasmosis within the first week of treatment. - Active CNS infections, malignancies or lesions not documented to be caused by histoplasmosis, which would interfere with assessment of response. - Unable to take oral medications reliably. - Severe malabsorption syndrome. - Requiring cytotoxic therapy for malignancies. - Any systemic fungal infection other than histoplasmosis. - Systemic Mycobacterium avium intracellulare. - Receiving treatment for other acute opportunistic infections whose signs and symptoms have not yet resolved or stabilized. Prior Medication: Excluded for greater than 1 week within the last 3 months: - Fluconazole. - Itraconazole. - SCH 39304. - Amphotericin B greater than 1.5 mg/kg, or any other antifungal for this episode of disseminated histoplasmosis. Patients who the investigator feels would be undependable with regard to adherence to the protocol.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Itraconazole


Locations

Country Name City State
United States Northwestern University CRS Chicago Illinois
United States Univ. of Cincinnati CRS Cincinnati Ohio
United States The Ohio State Univ. AIDS CRS Columbus Ohio
United States Duke Univ. Med. Ctr. Adult CRS Durham North Carolina
United States Indiana Univ. School of Medicine, Infectious Disease Research Clinic Indianapolis Indiana
United States USC CRS Los Angeles California
United States University of Minnesota, ACTU Minneapolis Minnesota
United States Tulane Med. Ctr. - Charity Hosp. of New Orleans, ACTU New Orleans Louisiana
United States Cornell University A2201 New York New York
United States Pitt CRS Pittsburgh Pennsylvania
United States Univ. of Rochester ACTG CRS Rochester New York
United States Washington U CRS Saint Louis Missouri

Sponsors (2)

Lead Sponsor Collaborator
National Institute of Allergy and Infectious Diseases (NIAID) Janssen Pharmaceuticals

Country where clinical trial is conducted

United States, 

References & Publications (2)

Hecht FM, Wheat J, Korzun AH, Hafner R, Skahan KJ, Larsen R, Limjoco MT, Simpson M, Schneider D, Keefer MC, Clark R, Lai KK, Jacobson JM, Squires K, Bartlett JA, Powderly W. Itraconazole maintenance treatment for histoplasmosis in AIDS: a prospective, multicenter trial. J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Oct 1;16(2):100-7. — View Citation

Wheat J, Hafner R, Korzun AH, Limjoco MT, Spencer P, Larsen RA, Hecht FM, Powderly W. Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trial Group. Am J Med. 1995 Apr;98(4):336-42. — View Citation

See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2